The objective of this study was to analyze the efficacy and safety of silodosin in patients with lower urinary tract symptoms (LUTS) associated with benign prostatic hyperplasia (BPH) in current urologic practice.
METHOD: This was a prospective observational study conducted by 272 urologists on patients treated by silodosin for BPH. The parameters evaluated were the weighted IPSS score, the IPSS question 8 related to quality of life, the USP score and the Athens Insomnia Scale (AIS) measured at treatment initiation and after 3 months.
RESULTS: Nine hundred and fourteen patients whose average age was 66 years with LUTS for 3.3 years were analyzed. After 3 months of treatment, a significant decrease in IPSS (from 16.2 ± 6.1 to 9.7 ± 5.5, P< 0.0001) and USP score (from 10.6 ± 5.1 to 6 0 ± 4.6, P< 0.0001) were observed, quality of life (from 67.1% to 14.4% of unsatisfied patients, P< 0.0001) and sleep were significantly improved (from 49.2% to 28.9% patients with insomnia, P< 0.0001). Among the patients, 21.2% experienced at least one adverse event. The most frequent were abnormal ejaculation (17.2%). And 7.1% discontinued the treatment for this reason. After 3 months of treatment silodosin was continued in 86.9% of patients.
CONCLUSION: This large study confirmed the efficacy of silodosin in LUTS associated with BPH with a safety profile that does not affect patient satisfaction.
Written by:
Descazeaud A, Davin JL, De La Taille A, Karsenty G, Kouri G, Zerbib M, Morris V, Allaert FA, Coloby P. Are you the author?
Service d'urologie, CHU, 87042 Limoges, France; Service d'urologie, clinique Rhône Durance, 84000 Avignon, France; Service d'urologie, CHU Henri-Mondor, 94000 Créteil, France; Service d'urologie, hôpital de la Conception, 13015 Marseille, France; Service d'urologie, polyclinique Francheville, 24004 Périgueux, France; Service d'urologie, polyclinique Francheville, 24004 Périgueux, France; Service d'urologie, CHU Cochin, 75014 Paris, France; Direction médicale, Bouchara-Recordati, 92800 Puteaux, France; Chaire d'évaluation médicale, CHU de Dijon, 21000 Dijon, France; Service d'urologie, hôpital Dubos, 95300 Cergy Pontoise, France.
Reference: Prog Urol. 2014 Mar;24(3):196-202.
doi: 10.1016/j.purol.2013.12.002
PubMed Abstract
PMID: 24560210
Article in French.
